Home Compare DGE.L vs REGN
Stock Comparison · Single-driver result

Diageo vs Regeneron Pharmaceuticals: Which Stock Looks Stronger in 2026?

Regeneron Pharmaceuticals holds the cleaner structural position, with stability as the main driver and valuation adding further support. Diageo still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, Regeneron Pharmaceuticals is in better shape — its trend is intact while Diageo's trend has broken down. That puts structure and market broadly in agreement — Regeneron Pharmaceuticals's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison is mainly decided in stability, with the rest of the profile carrying less weight. The overall score gap is 11 points in favour of Regeneron Pharmaceuticals, Inc..

Trajectory Similarity
0.61
Moderately similar
Peer-set rank: #28
within Diageo plc's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The clearest structural overlap shows up in recent revenue growth and margin trend.

Similarity drivers
recent revenue growthmargin trend
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
DGE.L
Diageo plc
50
Peer-Score
Signal qualityMedium
vs
REGN
Regeneron Pharmaceuticals, Inc.
61
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in stability.

Dimension spread: DGE.L vs REGN Profitability 63 63 Stability 17 65 Valuation 69 80 Growth 32 22 DGE.L REGN
Gap Ranking
#1 Stability +48
#2 Valuation +11
#3 Growth +10
#4 Profitability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DGE.L and REGN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DGE.LREGN Relative valuation Structural strength

Regeneron Pharmaceuticals, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
On stability, Regeneron Pharmaceuticals, Inc. ranks near the top of the group; Diageo plc sits in the weaker half.
Valuation
On valuation, the same pattern holds: both rank well, but Regeneron Pharmaceuticals, Inc. still sits higher.
Stability — Dominant Gap
DGE.L
17
REGN
65
Gap+48in favour of REGN

The clearest distance comes from a steadier profile over time.

What else supports the lead

Market confirmation also leans toward Regeneron Pharmaceuticals, Inc., which makes the lead look better backed by actual market behaviour.

What this means for the comparison

Stability is the clearest driver of the lead, with valuation adding further support — though growth still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the DGE.L vs REGN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar stability-driven comparisons

Explore how DGE.L and REGN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.